Chemotherapy is one of the primary treatments for malignant tumors. However, the acquired
drug resistance hinders clinical efficacy and leads to treatment failure in most patients …

Since the discovery of the first microRNAs (miRNAs, miRs), the understanding of miRNA
biology has expanded substantially. miRNAs are involved and described as master …

Cancer affects millions of people worldwide, and it is projected that there will be 1,958,310
new cancer cases and 609,820 cancer fatalities in the United States in 2023. Epirubicin …

Lung cancer continues to be a malignant tumor with high mortality. Two obstacles interfere
with curative therapy of lung cancer:(i) poor diagnosis at the early stages, as symptoms are …

The acquisition of cancer cell resistance to conventional chemotherapeutics is considered
the major driver of treatment failure and disease recurrence in most solid and hematological …

Sorafenib, a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC),
has been shown to be a potent ferroptosis inducer in HCC. However, we found that there …

Breast cancer (BC) is the most common malignancy among women worldwide. Like many
other cancers, BC therapy is challenging and sometimes frustrating. In spite of the various …

Adenocarcinoma is a common type of malignant tumor, originating from glandular epithelial
cells in various organs, such as pancreas, breast, lung, stomach, colon, rectus, and prostate …

HER2-positive breast cancer brain metastasis (HER2+ BCBM) is a refractory malignancy
with a high recurrence rate and poor prognosis. The efficacies of conventional treatments …

Cancer drug resistance remains a formidable challenge in modern oncology, necessitating
innovative therapeutic strategies. The convergence of intricate regulatory networks involving …